NIH-funded research R01 grant

Exploring weaknesses in harmful Gram-negative bacteria

Official title: Infection-Dependent Vulnerabilities of Gram-negative Bacterial Pathogens

Funded at University of Colorado · NIH-10900560 · Data updated 2026-11-12

This study is looking for new ways to fight infections caused by a type of bacteria called Salmonella by finding small molecules that can make these germs easier to treat when they hide inside our cells, with the hope of developing better therapies for people dealing with these infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Colorado
NIH-funded
Lab location1 site (Boulder, UNITED STATES)
Project startAugust 7, 2023
Project endJuly 31, 2027
Funding year2024
Award (this year)$475,749
NIH project number5R01AI168916-02
Project IDNIH-10900560 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are individuals suffering from infections caused by Gram-negative bacteria, particularly those caused by Salmonella.

Less likely to help

Patients with infections caused by Gram-positive bacteria or those who do not have bacterial infections may not benefit from this research.

What this research studies

This research investigates how certain Gram-negative bacteria, specifically Salmonella enterica serovar Typhimurium, can be targeted during infections. By using cell culture models, the researchers aim to identify small molecules that can exploit the vulnerabilities of these bacteria when they are inside human cells. The study focuses on understanding how the immune system affects the bacteria's outer membrane, making them more susceptible to treatment. If successful, this approach could lead to new therapies that effectively combat bacterial infections.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that effectively eliminate harmful Gram-negative bacterial infections.

How similar studies have gone: Other research has shown promise in targeting bacterial vulnerabilities, suggesting that this approach could lead to significant advancements in treatment.

Where this research is happening

  • University of Colorado
    Boulder, United States
    Active

Researchers

  • Principal investigator: Detweiler, Corrella S — University of Colorado
  • Study coordinator: Detweiler, Corrella S

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.